These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12769799)

  • 1. The vasopressin V1b receptor as a therapeutic target in stress-related disorders.
    Griebel G; Simiand J; Stemmelin J; Gal CS; Steinberg R
    Curr Drug Targets CNS Neurol Disord; 2003 Jun; 2(3):191-200. PubMed ID: 12769799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.
    Griebel G; Stemmelin J; Gal CS; Soubrié P
    Curr Pharm Des; 2005; 11(12):1549-59. PubMed ID: 15892661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.
    Serradeil-Le Gal C; Wagnon J; Tonnerre B; Roux R; Garcia G; Griebel G; Aulombard A
    CNS Drug Rev; 2005; 11(1):53-68. PubMed ID: 15867952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
    Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
    Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.
    Breuer ME; van Gaalen MM; Wernet W; Claessens SE; Oosting RS; Behl B; Korte SM; Schoemaker H; Gross G; Olivier B; Groenink L
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Jan; 379(1):101-6. PubMed ID: 18668225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin in health and disease with a focus on affective disorders.
    Zelena D
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):286-303. PubMed ID: 22954353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
    Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
    Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats.
    Salomé N; Stemmelin J; Cohen C; Griebel G
    Psychopharmacology (Berl); 2006 Aug; 187(2):237-44. PubMed ID: 16779555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat.
    Overstreet DH; Griebel G
    Pharmacol Biochem Behav; 2005 Sep; 82(1):223-7. PubMed ID: 16181667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415.
    Stemmelin J; Lukovic L; Salome N; Griebel G
    Neuropsychopharmacology; 2005 Jan; 30(1):35-42. PubMed ID: 15367924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.
    Iijima M; Yoshimizu T; Shimazaki T; Tokugawa K; Fukumoto K; Kurosu S; Kuwada T; Sekiguchi Y; Chaki S
    Br J Pharmacol; 2014 Jul; 171(14):3511-25. PubMed ID: 24654684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats.
    Zhou Y; Colombo G; Carai MA; Ho A; Gessa GL; Kreek MJ
    Alcohol Clin Exp Res; 2011 Oct; 35(10):1876-83. PubMed ID: 21575018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model.
    Iijima M; Chaki S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):622-7. PubMed ID: 17229509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.
    Alonso R; Griebel G; Pavone G; Stemmelin J; Le Fur G; Soubrié P
    Mol Psychiatry; 2004 Mar; 9(3):278-86, 224. PubMed ID: 14699428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat.
    Louis C; Cohen C; Depoortère R; Griebel G
    Neuropsychopharmacology; 2006 Oct; 31(10):2180-7. PubMed ID: 16452986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats.
    Shimazaki T; Iijima M; Chaki S
    Eur J Pharmacol; 2006 Aug; 543(1-3):63-7. PubMed ID: 16843459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders.
    Kehne JH
    CNS Neurol Disord Drug Targets; 2007 Jun; 6(3):163-82. PubMed ID: 17511614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic social defeat on behavioral and neural correlates of sociality: Vasopressin, oxytocin and the vasopressinergic V1b receptor.
    Litvin Y; Murakami G; Pfaff DW
    Physiol Behav; 2011 Jun; 103(3-4):393-403. PubMed ID: 21397619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.